65 results about "Beta defensin" patented technology

The invention relates to active ingredients capable of stimulating direct or indirect expression of type 2 human beta-defensins and/or type 3 human beta-defensins. The invention thus provides an active ingredient capable of stimulating direct or indirect expression of type 2 human beta-defensins and/or type 3 human beta-defensins, characterized in that said active ingredient does not cause any inflammatory, irritation or intolerance reactions. The invention also provides a screening method for the selection of such active ingredients. The invention is applicable to the preparation of cosmetic or pharmaceutical compositions containing such active ingredients.

The invention provides a method of inhibiting undesirable microbial contamination, invasion, or growth in an individual by administering to the individual an effective amount of a theta defensin. The invention additionally provides a method of inhibiting deleterious effects resulting from microbial contamination, invasion, or growth in an individual by administering to an individual an effective amount of a theta defensin, whereby immune-mediated pathology is limited and immune function is improved.

The invention provides a freeze-dried preparation for treating colpitis. The preparation includes an antimicrobial peptide freeze-dried powder and an antibacterial peptide basic liquid. The antibacterial peptide freeze-dried powder comprises the following components according to the total mass percentage: 0.1%-8% of an antibacterial peptide human beta defensin, 0.01%-0.2% of a low molecular weight heparin sodium and 1%-15% of a stabilizing agent; the antibacterial peptide basic liquid comprises the following components according to the total mass percentage: 0.01%-0.4% of hyaluronic acid, 0.5%-4% of menthoxypropanediol, 0.5%-5% of a honey extract, 0.5%-5% of PCA sodium, 0.5%-5% of dissolved protease, 0.3%-0.7% of 1,2 hexanediol, 1.5%-6% of oat beta dextran, 1%-5% soybean isoflavone, and the balance of deionized water or water for injection. The antimicrobial peptide freeze-dried preparation provided by the invention has broad-spectrum antibacterial activity, and strong killing effect on bacteria, fungi, viruses, protozoa and cancer cells, and even can enhance immunity, accelerate wound healing process; in addition, the preparation has obvious curative effect, and no rebound or side effect.

The invention relates to an antibacterial peptide GW13 and its preparation method and use. The antibacterial peptide GW13 has an amino acid sequence of GlyLeuArgProLysTyrSer(ArgTrpLeu)2-NH2. The preparation method comprises the following steps of 1, cutting out 13 amino acid fragments from a linear chicken beta-defensin 4 carboxyl end by a fixed-point amino acid fragment cutting method, removing disulfide bonds to obtain a GW10 (GlyLeuArgProLysTyrSerArgTrpLeu-NH2) fragment, and repeating connecting characteristic three-residue complexes ArgTrpLeu to obtain the antibacterial peptide GW13, and 2, synthesizing a peptide resin in a polypeptide synthesizer by a solid-phase synthesis method, carrying out TFA cutting to obtain a polypeptide, and carrying out reversed-phase high-performance liquid chromatography purification. The antibacterial peptide GW13 obtained by the preparation method has strong bacteriostatic activity, low hemolytic activity, the highest therapeutic index and a large development potential.

Disclosed are materials and methods for creating customizable traits in animals. In the demonstration of the principle of the subject invention, a keratin-14 specific promoter is used with red fluorescent protein in the loxp cassette, dominant black (ΔG23) beta defensin 103 in the pigment cassette, and an SV40 (with intron) polyadenylation sequence. When Cre recombinase (or HTNCre) is applied to the animal's skin in a carrier base (e.g., lipid bilayers), fur is permanently genetically modified to turn black in the shape in which the HTNCre was applied.

Disclosed are materials and methods for creating customizable traits in animals. In the demonstration of the principle of the subject invention, a keratin-14 specific promoter is used with, red fluorescent protein in the loxp cassette, dominant black (ΔG23) beta defensin 103 in the pigment cassette, and an SV40 (with intron) polyadenylation sequence. When Cre recombinase (or HTNCre) is applied to the animal's skin in a carrier base (e.g., lipid bilayers), fur is permanently genetically modified to turn black in the shape in which it was applied.

The present invention relates to treatment of an inflammatory bowel disease by simultaneous or successive parental and oral administration of a mammalian beta defensin.

A noninvasive method for measuring skin health in a subject comprising collecting an epithelial cell/skin cell sample from the subject; detecting a level of one or more antimicrobial peptide biomarkers in the epithelial cell sample/skin cell sample; diagnosing the subject as having a defense mechanism due to microbial attack on skin or a measure of the system being in balance with environment homeostasis based on the level of one or more antimicrobial peptide biomarkers selected from the group consisting of Histone H2B type 1-M, Histone H2A, Histone H4, Protein S100-A7, Protein S100-A8, Protein S100-A9, Cathepsin G, Neutrophil defensin 3 (Defensin, alpha 3) (HNP-3), Dermcidin, Ribonuclease 7 (RNase 7), human beta-defensin -2 (nBD-2) and Beta-defensin 103 (hBD-3) and listed in Table 1 wherein the AMP families include bactericidal permeability-increasing protein (BPI), Defensin, Histone, Pore-forming toxin, S100 protein, Cytotoxin, Serine Protease 51, Dual Oxidase, transcription regulation, and mixtures thereof. Further, a noninvasive method for evaluating the efficacy of products for skin health.

The invention provides a method for preparing natural antibiotics- recombined chicken- beta Buchner's bodies Gal-9. The invention employs molecular biology technology to clone chicken- beta Buchner's bodies Gal-9 gene from chicken, and expresses chicken- beta Buchner's bodies Gal-9 protein outside chicken body by using proper expression host. It is found by further research that the chicken- beta Buchner's bodies Gal-9 possesses wide anti bacteria activity and immunologic enhancement. The recombined chicken- beta Buchner's bodies Gal-9 is characterized in that: (1) ir can inhibit and kill bacillus coli, salmonella, Micrococcus pyogenes and so on, (2) prevents avian infectious brunchitis virus, (3) increases antibody for avian infectious brunchitis virus concentration by 10- 20 % in dimefox after oral administration for one week by chicken, improves apleen lymphocyte blastogenesis by 40- 50%.

Disclosed are materials and methods for creating customizable traits in animals. In the demonstration of the principle of the subject invention, a keratin-14 specific promoter is used with red fluorescent protein in the loxp cassette, dominant black ([Delta]G23) beta defensin 103 in the pigment cassette, and an SV40 (with intron) polyadenylation sequence. When Cre recombinase (or HTNCre) is applied to the animal's skin in a carrier base (e.g., lipid bilayers), fur is permanently genetically modified to tum black in the shape in which theHTNCre was applied.

The present invention relates to methods for modulating the intestinal microbiota by administering one or more defensins and/or GLP-1/GLP-1 analogs and methods for prevention or treatment of gut inflammation by oral administration of one or more defensins. GLP-1 analogs such as Liraglutide, as well as mammalian and poultry alfa and beta defensins can cause a change in the composition of the microbiota and metabolome in the intestine and can therefore be used to treat or prevent gut inflammation, colorectal cancer, metabolic syndrome, obesity, prediabetes and diabetes or as lean growth promoters in the meat production.

The present invention provides a human β-defensin secretion promoter that can be used in various forms, such as external preparation, internal preparation, food, etc., and promotes human β-defensin secretion. An organic acid has an effect of promoting the secretion of human β-defensin, particularly human β-defensin-2, and therefore the organic acid is used as an active ingredient of a human β-defensin secretion promoter. Furthermore, by adding the human β-defensin secretion promoter to external preparations, internal preparations, or foods, a human β-defensin secretion promotion effect can be imparted thereto.

The invention provides a method for preparing natural antibacterial agent- recombination chicken- beta defensins Gal-9-Gal-8 bi-molecule protein. The invention employs molecular biology technology and colones chicken- beta defensins Gal- 8 and Gal-9 gene inside chicken and expresses defensins Gal-9-Gal-8 bi-molecule protein outside chicken body by employing proper expression host. The recombined chicken- beta defensins Gal-9-Gal-8 bi-molecule protein is characterized in that: (1) it can inhibit and kill bacillus coli, salmonella and salmonella and so on, (2) it can resist avian infectious brunchitis and newcastle disease virus, (3) it can increase the antibody for avian infectious brunchitis in dimefox by 10-20%, antibody for newcastle disease virus by 10-20% and increase chicken splenocyte lymphocyte conversion rate by 60-70%.

A chicken intestinal tract Beta-defensin cDNA is characterized in that the cDNA has the following sequence: tcagacagcc agctgtgcag gaacaaccat ggccactgcc ggaggctctg cttccacatg gagagctggg ctgggagctg catgaacggc cgcctgcgct gctgcaggtt ctccaccaag cagccctttt ccaaccctaa acattcagtg ctgcacacag cagagcagga cccttcccca agccttggag ggacgtga. The amino acid sequence of the Beta-defensin is Ser-Asp-Ser-Gln-Leu Cys-Arg-Asn-Asn-His Gly-His-Cys-Arg- Arg Leu-Cys-Phe-His-Met Glu- Ser-Trp-Ala-Gly Ser-Cys-Met-Asn-Gly Arg-Leu-Arg-Cys-Cys Arg-Phe-Ser-Thr-Lys-Gln Pro-Phe-Ser-Asn-Pro Lys-His-Ser-Val-Leu His-Thr-Ala-Glu-Gln Asp-Pro-Ser-Pro-Ser Leu-Gly-Gly-Thr. The extraction method comprises the following steps of: (1) collecting broken mucosa cells of chicken intestinal tract; (2) breaking vesicles; (3) leaching with 5% acetic acid under stirring, centrifuging, collecting supernatant, removing sediment, subpackaging the supernatant and freeze-storing to obtain crude chicken intestinal tract Beta-defensin; (4) separating the supernatant with Sephadex G-100 gel column at low temperature, eluting with 0.2mol/L sodium acetate (constant flow pump speed 3*1), detecting with nucleic acid-protein detector, collecting the eluate with an automatic collector (1.5mL each tube), and recording with a recorder (speed 6cm/h, and range 20mV); (5) detecting the antibacterial activity of the liquid in each tube to Pasteurella with agarose diffusion method, collecting the eluate with bacteriostatic activity, and storing under vacuum freeze drying; (6) purifying the the eluate with bacteriostatic activity with Tricine-PAGE, PVDF membrane blotting the protein bands, and performing amino acid sequence analysis with Sanger partial hydrolysis method; and (7) deriving chicken intestinal tract Beta-defensin cDNA with BLAST software.

The invention discloses mature human beta-defensin-2 (HBD-2) and a preparation method thereof. The method comprises the following steps of: introducing glutamic residue between mature sequence and propeptide of HBD-2, obtaining HBD-2 pre-pro-peptide through recombination expression, obtaining HBD-2 pre-pro-peptide with higher purity via nickel column affinity chromatography purification, carrying out enzymolysis by using recombined bacillus licheniformis glutamic specific endopeptidase with an His(histidine)-tag, removing the propeptide and the affinity tag and removing the recombined bacillus licheniformis glutamic specific endopeptidase and other impurities through the affinity chromatography again, wherein the mature HBD-2 with higher purity exists in the solution. The preparation method of the mature HBD-2, disclosed by the invention, has the advantages of high efficiency, low cost and simplicity in purification process and accordingly lays a foundation for the large-scale preparation and the application of the mature HBD-2.

The invention discloses a pelteobagrus fulvidraco beta defensin gene, and beta defensin antibacterial peptide and application thereof. An in vitro recombinant expression technology is used for successfully expressing a pelteobagrus fulvidraco beta defensin recombinant protein PET-32a-Pf_BD, and antibacterial activity identification results show that the pelteobagrus fulvidraco beta defensin gene has a certain bacteriostasis for staphylococcus aureus in gram-positive bacterium, escherichia coli in gram-negative bacterium, aeromonas hydrophila, edwardsiella ictaluri and flavobacterium columnare. Therefore, a foundation is laid for application of the defensin recombinant protein, used as a broad-spectrum antibacterial drug, in aquaculture.

Cell-penetrating peptide and human Beta-defensin 3 fusion protein has 59 amino acids in full length, has a cell-penetrating peptide sequence at its nitrogen end and Beta-defensin 3 mature peptide sequence at its carbon end, and the two peptide segment are connected via double glycine and single serine and have molecular weight of 6.7 KD. The preparation method comprises the steps of acquiring a gene, constructing Pichia pastoris expression vector, constructing cell-penetrating peptide and human Beta-defensin 3 fusion protein Pichia pastoris genetically-engineered bacterium, fermenting cell-penetrating peptide and human Beta-defensin 3 fusion protein with Pichia pastoris, and purifying the cell-penetrating peptide and human Beta-defensin 3 fusion protein. Application of cell-penetrating peptide and human Beta-defensin 3 fusion protein in the preparation of bactericidal gels, application in the preparation of film cosmetics and application in the preparation of toner cosmetics are also provided.

The invention discloses a chicken lysozyme and chicken beta-defensin 7 fused gene. The nucleotide sequence of the chicken lysozyme and chicken beta-defensin 7 fused gene is shown as SEQ ID NO:1. Fused protein encoded by the fused gene has the amino acid sequence shown as SEQ ID NO:2. The invention further discloses a construction method of an expression vector of the fused gene, the fused protein prepared by adopting the expression vector has the obvious bacteriostasis activity for staphylococcus aureus, and the minimal inhibitory concentration is lower than 4mg/ml.

The invention is directed to beta-defensin-derived peptides and their use in modulating the activity of hematopoietic cells and other CXCR4-expressing cells. Specifically, the invention provides compositions and methods useful in the treatment of cancer. The invention further provides compositions and methods useful for promoting mobilization and transplantation of hematopoietic stem cells and progenitor cells.

The invention discloses preparation and an expression method of a chicken beta-defensin 9 yeast engineered bacteria, and belongs to the fields of biological technology and gene engineering pharmaceutical technology. The preparation process comprises: utilizing a pichia yeast consistently-used codon to optimize chicken beta-defensin 9 gene, adding a Kex2 restriction enzyme cutting site coding sequence at the front terminal of the gene, and artificially synthesizing the gene; then inserting the synthetic beta-defensin 9 gene sequence into a yeast constitutive expression vector, integrating into a the chromosome of a methylotrophy type pichia yeast by homologous recombination; and screening for multiple times to obtain the yeast engineered bacteria for producing chicken beta-defensin 9. The yeast engineered bacteria is capable of continuously performing high-level protein expression after fermentation and culturing, the expressed product is high in yield, is relatively close to the natural structure, is secreted in the broth, and also has relatively strong anti-foodborne pathogenic activity. The broth is subjected to preliminary separation and can be directly used as a forage additive after concentrated or dried, and the forage additive is applied to animal breeding industry, so that the production cost of defensin is reduced and the economic benefit of a production enterprise is improved. The technical scheme provided by the invention helps to establish a technological base for industrial large-scale production and application of beta-defensin 9 and development of poultry forage antibiotic additive substitutes.